Ubs Group Ag Fennec Pharmaceuticals Inc. Transaction History
Ubs Group Ag
- $400 Billion
- Q2 2024
A detailed history of Ubs Group Ag transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Ubs Group Ag holds 7,268 shares of FENC stock, worth $36,340. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,268
Previous 29,618
75.46%
Holding current value
$36,340
Previous $329,000
86.63%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding FENC
# of Institutions
65Shares Held
14.3MCall Options Held
10KPut Options Held
83.8K-
Southpoint Capital Advisors LP New York, NY4.08MShares$20.4 Million0.73% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$12 Million30.37% of portfolio
-
Dg Capital Management, LLC New York, NY1.63MShares$8.17 Million3.85% of portfolio
-
Solas Capital Management, LLC Darien, CT1.34MShares$6.7 Million4.92% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$5.94 Million0.0% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $130M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...